Zeiss Light and Electron Microscopy Combined in New Business Group
|
By LabMedica International staff writers Posted on 28 Nov 2011 |
The Carl Zeiss Group (Gottingen, Germany) has launched a new microscopy business group that combines microimaging and nanotechnology systems. In the future, the company will be the world's only supplier to offer one-stop, innovative systems, and solutions for light and electron microscopy.
Customers are increasingly using both systems and want integrated software and workflow solutions. The combination of Carl Zeiss MicroImaging and Nanotechnology Systems into one business group fully reflects this trend.
"By fusing the two worlds of microscopy, we are opening up totally new perspectives to our customers in science and industry," says Dr. Ulrich Simon, head of Carl Zeiss Microscopy. "Carl Zeiss has been a pioneer in this field for more than 160 years. Carl Zeiss and Ernst Abbe together invented scientific microscopy more than 160 years ago. Since then, the company has constantly played a crucial role in shaping the progress of this technology. We are now opening an exciting new chapter in this success story."
The potential offered by combining light and electron microscopy is illustrated by Prof. Jeff Lichtman of Harvard University (Cambridge, MA, USA), who is pioneering brain mapping with light and electron microscopy by generating three-dimensional maps of the brain.
Competition is increasing all over the world: microscopy is a fast-growing market because it is increasingly developing into a basic technology that is now firmly established in many different fields. It is a market that is characterized by big providers and small specialists for specific technologies. The new Carl Zeiss Microscopy business group combines two strengths: it has the right size to carry clout and offers technological expertise covering the entire microscopy process.
Related Links:
Carl Zeiss Group
Harvard University
Customers are increasingly using both systems and want integrated software and workflow solutions. The combination of Carl Zeiss MicroImaging and Nanotechnology Systems into one business group fully reflects this trend.
"By fusing the two worlds of microscopy, we are opening up totally new perspectives to our customers in science and industry," says Dr. Ulrich Simon, head of Carl Zeiss Microscopy. "Carl Zeiss has been a pioneer in this field for more than 160 years. Carl Zeiss and Ernst Abbe together invented scientific microscopy more than 160 years ago. Since then, the company has constantly played a crucial role in shaping the progress of this technology. We are now opening an exciting new chapter in this success story."
The potential offered by combining light and electron microscopy is illustrated by Prof. Jeff Lichtman of Harvard University (Cambridge, MA, USA), who is pioneering brain mapping with light and electron microscopy by generating three-dimensional maps of the brain.
Competition is increasing all over the world: microscopy is a fast-growing market because it is increasingly developing into a basic technology that is now firmly established in many different fields. It is a market that is characterized by big providers and small specialists for specific technologies. The new Carl Zeiss Microscopy business group combines two strengths: it has the right size to carry clout and offers technological expertise covering the entire microscopy process.
Related Links:
Carl Zeiss Group
Harvard University
Latest Industry News
- Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
- Diazyme Laboratories Acquires Carolina Liquid Chemistries
- Partnership Expands Access to Alzheimer’s Blood Tests in Latin America and Caribbean
- Global Multiplex Assays Market Driven by High-Throughput Diagnostic Demand
- GRAIL Presents Full Results from NHS-Galleri Trial at ASCO 2026
- Global Framework Integrates Digital Pathology for Companion Diagnostic Development
- Werfen and Oxford Nanopore Collaborate on Transplant Assay Development
- New Distribution Agreement Expands Access to CE-Marked Precision Oncology Assays
- ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026
- Artera to Highlight AI-Based Cancer Risk Stratification at ASCO 2026
- Natera to Present Data on MRD-Guided Cancer Care at ASCO 2026
- Fujifilm Integrates Structured Reporting into Digital Pathology Workflow
- Strategic Collaboration Advances RNA Foundation Models for Precision Oncology
- Partnership Brings Single-Cell Analysis into Clinical Oncology Workflows
- Partnership Aims to Bring Risk-Guided CKD Care to Health Systems
- AI-Powered Multi-Functional Analyzer Wins German Innovation Award
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more








